Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crestor Atherosclerosis Indication Adds Point Of Difference, Brand Leader Says

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca will build atherosclerosis benefit of Crestor into “messaging” of the statin to physicians, Commercial Brand Leader Nanfra says in an interview with “The Pink Sheet” DAILY.

You may also be interested in...



Clinical And Economic Implications Of Crestor JUPITER Study Headline ACC Meeting

Planet-struck American College of Cardiology kicks off its annual scientific session with a focus on the impact of AstraZeneca’s high-profile rosuvastatin study for medical practice and for the economics of cardiac health care.

Clinical And Economic Implications Of Crestor JUPITER Study Headline ACC Meeting

Planet-struck American College of Cardiology kicks off its annual scientific session with a focus on the impact of AstraZeneca’s high-profile rosuvastatin study for medical practice and for the economics of cardiac health care.

AstraZeneca’s GALAXY Studies And Plans For Crestor’s Ongoing Development

Company executives discuss on-going efforts to differentiate Crestor in the increasingly crowded cholesterol-lowering market.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel